Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ongoing trials and future prospects].

Samuele Baldasseroni1, Gianna Fabbri, Aldo Pietro Maggioni

  • 1Centro Studi ANMCO, Via La Marmora, 34 50121 Firenze.

Italian Heart Journal : Official Journal of the Italian Federation of Cardiology
|February 27, 2004
PubMed
Summary

Rosuvastatin effectively lowers LDL cholesterol and raises HDL cholesterol, offering significant cardiovascular benefits. Ongoing trials are assessing its impact on cardiovascular events in various patient groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extreme Cardiovascular Risk and LDL-C Target Achievement in People With HIV.

Open forum infectious diseases·2026
Same author

Blood pressure control in people with HIV and established atherosclerotic cardiovascular disease: a real-world descriptive analysis.

AIDS (London, England)·2026
Same author

[Eugene Braunwald obituary].

Giornale italiano di cardiologia (2006)·2026
Same author

Hospital at home for older patients with heart failure: an observational study of the GIROT experience.

European geriatric medicine·2026
Same author

A Geriatric Assessment Score Predicting 1-Year Mortality and Functional Decline After TAVR: The GASS-TAVR Study.

JACC. Cardiovascular interventions·2026
Same author

Challenges and Perspectives in Optimising the Treatment of Arterial Hypertension: Role of the Ramipril-Amlodipine-Hydrochlorothiazide Single-Pill Combination.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension·2026

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Lipidology

Context:

  • Rosuvastatin is a novel statin with unique pharmacological properties.
  • It exhibits selective binding to 3-hydroxy-3-methylglutaryl coenzyme A reductase.
  • Its hydrophilic nature and hepatic selectivity contribute to its efficacy.

Purpose:

  • To summarize the pharmacological benefits of rosuvastatin.
  • To highlight its efficacy in lipid profile modification.
  • To discuss ongoing research evaluating its clinical outcomes.

Summary:

  • Rosuvastatin demonstrates superior efficacy in reducing LDL cholesterol and increasing HDL cholesterol compared to other statins.
  • It is well-tolerated across a range of dosages.
  • Current research focuses on its impact on cardiovascular morbidity and mortality.

Impact:

  • Rosuvastatin offers a promising therapeutic option for managing dyslipidemia and reducing cardiovascular risk.
  • Further research will elucidate its role in specific patient populations, including those with renal disease and heart failure.
  • The GALAXY Programme and GISSI-HF trial are key initiatives investigating rosuvastatin's long-term cardiovascular effects.

Related Experiment Videos